Outcomes associated with the intention of loco-regional therapy prior to living donor liver transplantation for hepatocellular carcinoma

Table 1 The clinical features of patients based on the intention of loco-regional therapy before living donor liver transplantation

	Group I (n = 52)	Group II (n = 228)	Group III (n = 28)	P value
Age, median (range)	58 (13-70)	56 (33-69)	56 (38-69)	0.246
Sex
Male	39 (75.0)	186 (81.6)	24 (85.7)	0.437
Female	13 (25.0)	42 (18.4)	4 (14.3)
Hepatitis status, n (%)
Hepatitis B positive	25 (48.1)	152 (66.7)	19 (67.9)	0.181
Hepatitis C positive	17 (32.7)	51 (22.4)	7 (25.0)
HBV + HCV	6 (11.5)	10 (4.4)	1 (3.6)
None	4 (7.7)	15 (6.6)	1 (3.6)
MELD score, median (range)	15.5 (8-36)	10.0 (6-35)	9.5 (5-22)	< 0.0001
Child Class, n (%)				< 0.0001
A	9 (17.3)	116 (50.9)	16 (57.1)
B	17 (32.7)	81 (35.5)	8 (28.6)
C	26 (50.0)	31 (13.6)	4 (14.3)
AFP, median (range)	9.2 (2.0-1552)	11.8 (1.3-18250)	53.4 (2.0-461)	0.098
Graft type, n (%)				0.578
Left liver	2 (3.8)	16 (7.0)	1 (3.6)
Right liver	50 (96.2)	212 (93.0)	27 (96.4)
GRWR (%), n (%)				0.037
≤ 0.8	7 (13.5)	64 (28.1)	4 (14.3)
> 0.8	45 (86.5)	164 (71.9)	24 (85.7)
Tumor Number, median (range)	1 (1-20)	2 (1-22)	4 (1-20)	< 0.0001
Maximum tumor size, median (range)	2.1 (1.0-7.5)	2.5 (1.0-9.2)	3.4 (1.5-11.2)	0.006
Pathologic UCSF, n (%)				< 0.0001
Within	41 (78.8)	172 (75.4)	6 (21.4)
Beyond	11 (21.2)	56 (24.6)	22 (78.6)
Histology grade, n (%)				0.382
1-2	43 (82.7)	169 (74.1)	20 (71.4)
3-4	9 (17.3)	59 (25.9)	8 (28.6)

HBV: Hepatitis B virus; HCV: Hepatitis C virus; MELD: Model for end-stage liver disease; AFP: Alpha-fetoprotein; GRWR: Graft recipient weight ratio; UCSF: University of California San Francisco.